YIH
CAI

Y-Intercept (HK)’s Caris Life Sciences CAI Stock Holding History

Y-Intercept (HK)’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$821K Buy
+46,068
New +$825K 0.02% 1123

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Y-Intercept (HK)'s CAI Position: Q2 2026 in Review

Y-Intercept (HK) opened a new position in Caris Life Sciences (CAI) in Q2 2026: 46,068 shares worth $821K. The stake represents 0.02% of the portfolio and ranks #1123 among its holdings.

247 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • Y-Intercept (HK) held 46,068 shares of Caris Life Sciences worth $821K as of Q2 2026.
  • Caris Life Sciences was a new Y-Intercept (HK) position in Q2 2026.
  • Caris Life Sciences made up 0.02% of Y-Intercept (HK)'s portfolio in Q2 2026, its #1123 holding.
  • 247 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.